Patents by Inventor Andrew McMichael

Andrew McMichael has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240076350
    Abstract: The invention relates to a mutant HLA-E heavy chain comprising one or more mutation which permits the formation of a HLA-E:peptide complex with increased stability when compared to the complex without the mutant HLA-E heavy chain. The invention also relates to a peptide which is capable of being crosslinked to the mutant HLA-E heavy chain, and a protein complex comprising or consisting of the mutant HLA-E heavy chain and peptide.
    Type: Application
    Filed: December 31, 2021
    Publication date: March 7, 2024
    Inventors: Andrew MCMICHAEL, Geraldine GILLESPIE, Max QUASTEL
  • Publication number: 20240024477
    Abstract: The invention relates to a T cell receptor (TCR) which is HIV-1 specific and HLA-E restricted. Particularly, the TCR is capable of binding to a peptide of RMYSPTSIL or a peptide of RMYSPTSIL in complex with HLA-E, or a peptide of ILVESPAVL or a peptide of ILVESPAVL in complex with HLA-E. The invention also relates to a nucleic acids and vector encoding the TCR.
    Type: Application
    Filed: December 2, 2021
    Publication date: January 25, 2024
    Inventors: Honbing YANG, Geraldine GILLESPIE, Margarida REI, Simon BRACKENRIDGE, Andrew MCMICHAEL, Hong SUN
  • Patent number: 11235055
    Abstract: Disclosed herein are mosaic conserved region HIV polypeptides and immunogenic polypeptides including one or more of the mosaic conserved region polypeptides. In some embodiments, the immunogenic polypeptides are included in an immunogenic composition, such as a polyvalent immunogenic composition. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject having or at risk of HIV infection. In some embodiments, the methods include inducing an immune response in a subject comprising administering to the subject at least one of the disclosed immunogenic polypeptides or a nucleic acid encoding at least one of the immunogenic polypeptides.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: February 1, 2022
    Assignees: Triad National Security, LLC, Isis Innovation Limited
    Inventors: Bette T. M. Korber, Tomas Hanke, Andrew McMichael
  • Publication number: 20190151440
    Abstract: Disclosed herein are mosaic conserved region HIV polypeptides and immunogenic polypeptides including one or more of the mosaic conserved region polypeptides. In some embodiments, the immunogenic polypeptides are included in an immunogenic composition, such as a polyvalent immunogenic composition. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject having or at risk of HIV infection. In some embodiments, the methods include inducing an immune response in a subject comprising administering to the subject at least one of the disclosed immunogenic polypeptides or a nucleic acid encoding at least one of the immunogenic polypeptides.
    Type: Application
    Filed: June 29, 2018
    Publication date: May 23, 2019
    Applicants: Los Alamos National Security, LLC, Oxford University Innovation Limited
    Inventors: Bette T. M. Korber, Tomas Hanke, Andrew McMichael
  • Patent number: 10010606
    Abstract: Disclosed herein are mosaic conserved region HIV polypeptides and immunogenic polypeptides including one or more of the mosaic conserved region polypeptides. In some embodiments, the immunogenic polypeptides are included in an immunogenic composition, such as a polyvalent immunogenic composition. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject having or at risk of HIV infection. In some embodiments, the methods include inducing an immune response in a subject comprising administering to the subject at least one of the disclosed immunogenic polypeptides or a nucleic acid encoding at least one of the immunogenic polypeptides.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: July 3, 2018
    Assignees: Los Alamos National Security, LLC, Oxford University Innovation Limited
    Inventors: Bette T. M. Korber, Tomas Hanke, Andrew McMichael
  • Publication number: 20160213772
    Abstract: Disclosed herein are mosaic conserved region HIV polypeptides and immunogenic polypeptides including one or more of the mosaic conserved region polypeptides. In some embodiments, the immunogenic polypeptides are included in an immunogenic composition, such as a polyvalent immunogenic composition. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject having or at risk of HIV infection. In some embodiments, the methods include inducing an immune response in a subject comprising administering to the subject at least one of the disclosed immunogenic polypeptides or a nucleic acid encoding at least one of the immunogenic polypeptides.
    Type: Application
    Filed: September 30, 2014
    Publication date: July 28, 2016
    Applicants: Los Alamos National Security, LLC, Isis Innovation Limited
    Inventors: Bette T.M. Korber, Tomas Hanke, Andrew McMichael
  • Patent number: 7993651
    Abstract: Disclosed is an immunogen in sterile form suitable for administration to a human subject, the immunogen comprising: at least a portion of the gag protein of HIV, said gag protein being from an HIV clade or having a consensus sequence for one or more HIV clades, and comprising at least parts of p17 and p24; and a synthetic polypeptide comprising a plurality of amino acid sequences, each sequence comprising a human CTL epitope of an HIV protein, and wherein a plurality of HIV proteins are represented in the synthetic polypeptide, said CTL epitopes being selected to stimulate an immune response to one or more HIV clades of interest.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: August 9, 2011
    Assignees: Medical Research Council, International AIDS Vaccine Initiative, University of Nairobi
    Inventors: Tomas Hanke, Andrew McMichael
  • Publication number: 20110159034
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
    Type: Application
    Filed: November 5, 2010
    Publication date: June 30, 2011
    Inventors: Andrew McMICHAEL, Adrian V.S. Hill, Sarah C. Gilbert, Jörg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
  • Publication number: 20100119551
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
    Type: Application
    Filed: June 19, 2009
    Publication date: May 13, 2010
    Inventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
  • Publication number: 20090324632
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
    Type: Application
    Filed: May 15, 2009
    Publication date: December 31, 2009
    Applicant: Oxxon Therapeutics Ltd.
    Inventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
  • Publication number: 20090191237
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
    Type: Application
    Filed: August 4, 2008
    Publication date: July 30, 2009
    Applicant: Oxxon Therapeutics Limited
    Inventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
  • Patent number: 7514087
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumor antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
    Type: Grant
    Filed: April 28, 2004
    Date of Patent: April 7, 2009
    Assignee: Oxxon Therapeutics Limited
    Inventors: Andrew McMichael, Adrian V. S. Hill, Sarah C. Gilbert, Jörg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
  • Patent number: 7407661
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
    Type: Grant
    Filed: April 28, 2004
    Date of Patent: August 5, 2008
    Assignee: Oxxon Therapeutics Limited
    Inventors: Andrew McMichael, Adrian V. S. Hill, Sarah C. Gilbert, Jörg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
  • Publication number: 20080089901
    Abstract: The present invention provides artificial fusion proteins (AFPs) designed to elicit an anti-HIV immune response, as well as nucleic acid molecules and expression vectors encoding those proteins. The AFPs of the invention may comprise domains from various HIV proteins, such as Gag, Pol, Vif, and Env proteins, which are partial sequences. HIVCON is an AFP in which the HIV domains are from several HIV clade consensus sequences and which optionally contains additional domains which may be useful, for example, in monitoring expression levels or laboratory animal immune responses. Other aspects of the invention may include compositions and methods for inducing an anti-HIV immune response in a subject, preferably with a DNA prime-MVA boost strategy, and to induce a cell-mediated immune response.
    Type: Application
    Filed: August 23, 2007
    Publication date: April 17, 2008
    Inventors: Tomas Hanke, Andrew McMichael
  • Publication number: 20040213799
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
    Type: Application
    Filed: October 16, 2003
    Publication date: October 28, 2004
    Applicant: Oxxon Pharmaccines Limited
    Inventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
  • Publication number: 20040197349
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
    Type: Application
    Filed: April 28, 2004
    Publication date: October 7, 2004
    Applicant: Oxxon Therapeutics Ltd.
    Inventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
  • Publication number: 20040191272
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
    Type: Application
    Filed: April 28, 2004
    Publication date: September 30, 2004
    Applicant: Oxxon Therapeutics Ltd.
    Inventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
  • Publication number: 20040175365
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
    Type: Application
    Filed: April 28, 2004
    Publication date: September 9, 2004
    Applicant: Oxxon Therapeutics Ltd.
    Inventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
  • Publication number: 20040131594
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
    Type: Application
    Filed: September 2, 2003
    Publication date: July 8, 2004
    Inventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
  • Patent number: 6663871
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
    Type: Grant
    Filed: December 9, 1999
    Date of Patent: December 16, 2003
    Assignee: Oxxon Pharmaccines Ltd.
    Inventors: Andrew McMichael, Adrian V. S. Hill, Sarah C. Gilbert, Jörg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard